Background and Aims: Antifibrotic therapies reduce lung function decline in patients with idiopathic pulmonary fibrosis (IPF). This single‐arm, open‐label, nonrandomized study aimed to determine the influence of antifibrotic treatment on patients' reported symptoms and expectations of the therapy.Methods: Fifty‐two patients with confirmed IPF at a mean age of 65 ± 8.63 years (73% male) completed the following surveys at baseline and after 12 months of Pirfenidone treatment: Short Form Healthy Survey (SF‐36), St. George's Respiratory Questionnaire (SGRQ), Baseline Dyspnea Index (BDI), Fatigue Assessment Scale (FAS), Leicester Cough Questionnaire (LCQ), and Patient's Needs and Expectations Authors' Survey.Results: The most important patients' needs were access to novel therapy, fast and easy access to health centers specializing in IPF treatment, and the improvement of the general condition or the maintenance of its level. These needs did not change with time, except for the significantly more important right of deciding on disease management after 12 months of treatment (p = 0.014). The quality of life per SF‐36, after 1 year of Pirfenidone treatment, significantly improved in the physical cumulative score (p = 0.004) and mental cumulative score (p = 0.003). Significant deteriorations were observed in bodily pain and vitality. For the remaining questionnaires (SGRQ, BDI, FAS, and LCQ), no significant changes in the course of the study were noticed. Around one in 10 patients subjected to Pirfenidone therapy had achieved general symptom improvement in all areas; that is, quality of life improvement as well as cough and dyspnea reduction.Conclusions: One year of antifibrotic treatment resulted in a general improvement in the quality of life per the SF‐36 questionnaire. Patients' expectations of disease management did not change; also, access to novel therapies and easy access to health centers specializing in IPF management remained their top needs.

(1) Background: Pulmonary rehabilitation (PR) plays a significant therapeutic role for patients with idiopathic interstitial pneumonia (IIP). The study assessed the impact of physical activity on lung function measured by forced oscillation technique (FOT). (2) Methods: The study involved 48 patients with IIP subjected to a 3-week inpatient PR. The control group included IIP patients (n = 44) on a 3-week interval without PR. All patients were assessed at baseline and after 3 weeks of PR by FOT, spirometry, plethysmography, grip strength measurement and the 6-minute walk test. (3) Results: There were no significant changes in FOT measurements in the PR group, except for reduced reactance at 11 Hz, observed in both groups (p < 0.05). Patients who completed PR significantly improved their 6-min walk distance (6MWD) and forced vital capacity (FVC). The change in 6MWD was better in patients with higher baseline reactance (p = 0.045). (4) Conclusions: Patients with IIP benefit from PR by an increased FVC and 6MWD; however, no improvement in FOT values was noticed. Slow disease progression was observed in the study and control groups, as measured by reduced reactance at 11 Hz. Patients with lower baseline reactance limitations achieve better 6MWD improvement.

Background: Lung transplantation (LTx) remains the final therapeutic option for patients with end-stage and irreversible respiratory failure. The most common complication after LTx is chronic lung allograft dysfunction (CLAD), which affects long-term outcomes. However, CLAD may be partially reversible, especially after early detection of the cause. For this reason, systematic monitoring of transplanted lung function, including spirom-etry values, is so important. In these cases, the usage of modern technologies and tele-medicine can be extremely useful and allow for early response to possible decreases of spirometry values. Objective: The aim of our study is to evaluate the feasibility and clinical usefulness of spirometry telemonitoring in lung transplant patients. Methods: This retrospective study compared lung transplant recipients, where the first group of patients was subjected to spirometry telemonitoring (N=21), the second group was monitored with standard home spirometry (N=23), and the control group underwent routine follow-ups only in the transplant center (N=32). Results: The mean number of emergency visits was found to be lower in the telemoni-toring vs routine care group (1.24 vs 2.34, P=.05). Additionally, the mean duration of all visits was higher in the routine care group (10.0 days) in comparison to the telemonitoring group (5.8 days, P< .001) and to the standard home spirometry group (8.7 days, P=0.03). Conclusions: Spirometry telemonitoring using digital devices is not only feasible in lung transplant recipients, but it may provide substantial clinical benefits in this group of patients. It makes it possible to react faster in the event of abnormalities, which results in a reduction in the number of emergency visits and their duration.

BACKGROUND Lung transplantation (LTx) remains the final therapeutic option for patients with end-stage and irreversible respiratory failure. The most common complication after LTx is chronic lung allograft dysfunction (CLAD), which affects long-term outcomes. However, CLAD may be partially reversible, especially after early detection of the cause. For this reason, systematic monitoring of transplanted lung function, including spirometry values, is so important. In these cases, the usage of modern technologies and telemedicine can be extremely useful and allow for early response to possible decreases of spirometry values. OBJECTIVE The aim of our study is to evaluate the feasibility and clinical usefulness of spirometry telemonitoring in lung transplant patients. METHODS This retrospective study compared lung transplant recipients, where the first group of patients was subjected to spirometry telemonitoring (N=21), the second group was monitored with standard home spirometry (N=23), and the control group underwent routine follow-ups only in the transplant center (N=32). RESULTS The mean number of emergency visits was found to be lower in the telemonitoring vs routine care group (1.24 vs 2.34, P=.05). Additionally, the mean duration of all visits was higher in the routine care group (10.0 days) in comparison to the telemonitoring group (5.8 days, P<.001) and to the standard home spirometry group (8.7 days, P=0.03). CONCLUSIONS Spirometry telemonitoring using digital devices is not only feasible in lung transplant recipients, but it may provide substantial clinical benefits in this group of patients. It makes it possible to react faster in the event of abnormalities, which results in a reduction in the number of emergency visits and their duration. CLINICALTRIAL BNW/NWN/0052/KB/47/24